858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting - Morningstar
·
0 reactions
·
0 comments
·
13 views
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Original article
Google News
Anonymous · no account needed